Studies support reduced risk potential of the Vype ePen e-cigarette

(R&D at British American Tobacco) Tests on Vype ePen, a commercially available e-cigarette, reveal the relatively simple nature of Vype ePen vapor compared to cigarette smoke, that it has little or no impact on human cells in certain lab-based tests and that it effectively delivers nicotine to the userThe results of one test are important, but the combined results of all these tests build a picture of a product with the potential to be substantially reduced-risk compared to cigarettes.
Source: EurekAlert! - Social and Behavioral Science - Category: International Medicine & Public Health Source Type: news